Background
==========

Human immunodeficiency virus (HIV) infection has a variety of effects on hematopoiesis. Pancytopenia is part of its natural history.[@b1-idrt-6-2013-025]--[@b4-idrt-6-2013-025] Cytopenia is a common complication of infection with human immunodeficiency virus type 1 (HIV-1), and, in the course of the disease, more than 70% of the patients develop anemia, frequently requiring transfusion.[@b5-idrt-6-2013-025] Neutropenia, lymphopenia, and thrombocytopenia may occur indicating that more than one hemopoietic lineage may be impaired. Dysfunction of the bone marrow has been suggested as a possible mechanism; the degree of cytopenia often reflects the severity of the disease.[@b6-idrt-6-2013-025] HIV-1 infection of marrow stromal cells is sufficient to result in anemia and other cytopaenias.[@b7-idrt-6-2013-025]--[@b9-idrt-6-2013-025] A decrease in serum erythropoietin levels,[@b10-idrt-6-2013-025] autoantibodies to erythropoietin, or marrow suppression by opportunistic infections, tumors or various medications,[@b11-idrt-6-2013-025]--[@b14-idrt-6-2013-025] may also contribute to the cytopenia commonly observed in HIV-infected persons. Highly active antiretroviral therapy (HAART) may ameliorate many of these effects in an indirect manner simply by decreasing the HIV viral burden[@b15-idrt-6-2013-025]--[@b17-idrt-6-2013-025] and stimulating hematopoietic progenitor cell growth.[@b18-idrt-6-2013-025] Although HAART use in HIV infection has generally been accepted as the gold standard in the management of HIV patients,[@b19-idrt-6-2013-025] some antiretroviral drugs (ie, nucleoside analogue reverse transcriptase inhibitors, especially zidovudine) may cause anemia or worsen existing anemia, and, for this reason, zidovudine is usually excluded from the antiretroviral regimen of severely anaemic patients.[@b20-idrt-6-2013-025] The most troublesome and common toxicities of zidovudine are, notably, anemia and neutropenia.[@b20-idrt-6-2013-025] There are conflicting reports on the impact of HAART in resolving hematological complications. Whereas some studies have reported improvements in hematocrit and hemoglobin values resulting in reduction in morbidity and mortality of HIV patients,[@b19-idrt-6-2013-025],[@b21-idrt-6-2013-025] another study has reported no improvement in hematocrit values of HAART-treated HIV patients compared with HAART-naive patients.[@b22-idrt-6-2013-025] This current study was designed to assess the impact of HAART in resolving immunological and hematological complications in HIV patients by comparatively analyzing the results (immunological and hematological) of HAART-naive patients and those on HAART in our environment.

Methods
=======

Study area and design
---------------------

This cross-sectional study was carried out in the Department of Medicine, University of Maiduguri Teaching Hospital, Borno State, from September 2007 through March 2008. This is a 500 bed hospital designated as a Centre of Excellence for infectious diseases and provides primary, secondary and tertiary services for the North Eastern part of Nigeria. It also caters for the neighboring countries such as the Republics of Cameroon, Niger, and Chad. Permission was obtained from the University of Maiduguri Teaching Hospital (UMTH) Ethical Committee. Written informed consent (signed or thumb print) was obtained from patients.

### Study population and procedure

A total of 536-HIV positive patients were consecutively recruited into the study. Using a structured, pre-evaluated questionnaire, information was obtained on demographic characteristics, clinical manifestations, medication used, blood transfusions, and sexual and drug use behavior. The study population consisted of HAART-naive patients and patients who had been on HAART for ≥ 12 months. Criteria for HAART initiation for patients on therapy was based on the Centers for Disease Control and Prevention (CDC) criteria.[@b23-idrt-6-2013-025] HAART use was defined as receipt of two nucleoside reverse transcriptase inhibitors (NRTIs) and one non-nucleoside reverse transcriptase inhibitor (NNRTI) or one protease inhibitor (PI). The HAART regimen was verified from patient's clinical records. Pregnant patients and patients on medications that could affect the hematological system (antibiotics, vitamin supplements, or tuberculosis treatment) at the time of sampling were excluded from the study.

Blood sample analysis
---------------------

The HIV serological reactivity was determined by enzyme-linked immunoassay (ELISA) and confirmed by western blot analysis. Samples for CD4+ T-cell count were collected between 9:00 AM and 10:00 AM and assayed within 6 hours of collection of whole blood using standardized flow cytometric Cyflow machine (Cytec Development Inc, Partec, Germany). Hemoglobin (Hb), total white blood count (WBC), lymphocyte percentage, and plateletes were analyzed using a hematology analyzer (Sysmex^®^ Corporation, Kobe, Japan). Plasma HIV RNA levels were measured using freshly frozen specimens separated within 6 hours of phlebotomy utilizing the Amplicor HIV-1 Monitor Test, version 1.5 (Roche^®^, Germany), with a minimum cutoff value of 200 copies per mL.

Statistical Analysis
====================

The software program SPSS version 15 (SPSS Inc, Chicago, IL) was used. Results are presented as means ± SEM. Unpaired *t* tests were used to compare the means of all continuous variables. Categorical data were analyzed using Fisher exact test or Chi-sqaure test for trend. Linear regression was used to test for the degree of association between test parameters. A *P* value of \<0.05 was considered to be statistically significant.

Demographic and social characteristics of the study population
--------------------------------------------------------------

Of the 536 participants that were consecutively recruited into the study, 36 had incomplete or missing records and were excluded from the analysis. Records of 500 subjects were complete, comprising 315 (63%) HAART-naive and 185 (37%) HAART-experienced participants, with median ages of 27.09 ± 16.92 (range, 17--70 years) and 34.43 ± 15.06 (range, 18--67 years), respectively (*P* \< 0.001). Of the 315 HAART-naive participants, 119 (37.8%) were male, and 196 (62.2%), female, with median ages 32.28 ± 17.91 (range, 17--67) years and 24.72 ± 14.89 (range, 17--70) years, respectively (*P* \< 0.001). Of the 185 HAART-experienced participants, 67 (36.2%) were male, while 118 (63.8%) were female, with median ages 38.77 ± 14.81 (range, 20--67) years and 34.08 ± 12.45 (range 18--66) years (*P* \< 0.001), respectively. The age profile as depicted in [Table 1](#t1-idrt-6-2013-025){ref-type="table"} indicates that the majority of the of the participants were \<50 years, with the highest proportion (32.1%) from 30 to 39 years of age in HAART-naive participanats, while 40% of HAART-experienced participants were from 40 to 49 years of age. Heterosexual transmission was the presumed risk factor in almost all the study participants. Categorization of the participants based on educational attainment shows that a quarter of the participant had no western education; the majority of the educated had secondary education. Almost half of HAART naïve and one-third of HAART experienced were married, quarter of the studied participants were single in both group, while HAART experienced had more divorced participants as presented in [Figure 1](#f1-idrt-6-2013-025){ref-type="fig"}. Demographic and social characteristics of the study participants evaluated in this study are presented in [Table 1](#t1-idrt-6-2013-025){ref-type="table"}.

Hematological profile, viral load, and cytopenic tendency stratified by HAART use
---------------------------------------------------------------------------------

The mean hemoglobin of 11.89 ± 1.61 (95% confidence interval \[CI\], 11.64--12.13) in HAART-experienced participants was significantly higher than the mean hemoglobin of 9.76 ± 2.82 (95% CI, 9.45--10.07) in HAART-naive participants (*P* \< 0.001). Using packed cell volume (PCV) \<30% to define anemia, 57.5% (180/313) of HAART-naive participants were 3 times at risk of anemia compared with 24.3% (41/169) or HAART-experienced participants (*P* \< 0.001). The mean WBC and the incidence of leukopenia were higher among HAART----naive participants (*P* \< 0.001). The mean total leukocyte count (TLC) of 2.05 ± 1.34 (95% CI, 1.86--2.24) in HAART-experienced participants was significantly higher than the mean TLC of 1.61 ± 1.02 (95% CI, 1.50--1.72) in HAART-naive participants (*P* \< 0.001), consequently HAART-naive participants had 4 times the risk of developing leukopenia (TLC \< 2500 μL^−1^) than HAART-experienced participants (*P* \< 0.001). The mean lymphocyte % of 46.11 ± 12.70 (95% CI, 44.27--47.90) and incidence of lymphopenia (\<40%) of 98.3% were significantly higher in HAART-experienced participants than 31.85 ± 12.37 (95% CI, 30.43--33.28) and 73.2% in HAART-naive participants (*P* \< 0.001). The mean neutrophil % of 54.98 ± 15.72 (95% CI, 53.22--56.73) in HAART- naive participants was higher than 38.35 ± 10.49 (95% CI, 36.82--39.87) in HAART-experienced participants (*P* \< 0.001), conversely neutropenia defined as neutrophil % (NC%) % \< 60% showed HAART-experienced preponderance (*P* \< 0.001). Although there was no difference in mean platelets counts, the risk of thrombocytopenia (\<150 × 10^3^/μL) was 8 times higher in HAART-naive participants (*P* \< 0.001). The mean CD4 count of 347.73 ± 183.85 (95% CI, 320.77--374.70) was significantly higher in HAART-experienced than 238.98 ± 216.57 (95% CI, 214.93--263.03) in HAART-naive participants (*P* \< 0.001), the risk of immunological AIDS (\<200 cell/μL) was 3 times in HAART naive than HAART experienced (*P* \< 0.001). The mean viral load log10 was significantly lower in HAART experienced (3.17 ± 1.04) copies/mL than 5.58 ± 2.23 copies/mL in HAART-naive participants (*P* \< 0.001). The haematological profile, viral load and cytopenic tendency of the participants stratified by HAART use is as presented in [Table 2](#t2-idrt-6-2013-025){ref-type="table"}. The incidence of cytopenia in the study population is as shown in [Figure 2](#f2-idrt-6-2013-025){ref-type="fig"}.

World Health Organization Clinical Trials Group, anemia toxicity, stratified CD4 count by CDC and TLC grades
------------------------------------------------------------------------------------------------------------

Classification of the study population according to the World Health Organization/AIDS Clinical Trials Group (WHO/ACTG) anemia toxicity grades as presented in [Table 3](#t3-idrt-6-2013-025){ref-type="table"} gave a 60.1% and 36.1% calculated incidence of anemia (Hb \< 10.5 g/dL^−1^) in HAART-naive and HAART-experienced participants respectively (*x*^2^ = 17.54, *P* \< 0.001). The odds of developing grade 1 anemia in HAART-naive and HAART-experienced participants were similar (*P* = 0.18); however, HAART-naïve participants were 2 times at risk of developing grade 2 anemia (*P* \< 0.001). Grade 3 and 4 anemia were not seen in HAART-experienced patients.

The Centers for Disease Control and Prevention (CDC) criteria were used to classify the study population into three categories based on CD4 counts: stage 1 (CD4 \> 500 cells/μL), stage 2 (CD4 between 200 and 499 cells/μL) and stage 3 (CD4 \< 200 cells/μL). The risk of having CD4 count \< 200 cells/μL was thrice in HAART-naive participants than those on HAART (*P* \< 0.001), and the chances of having a CD4 count between 200 and 499 cells/μL was 2 times higher in patients on HAART than those who were HAART naive (*P* = 0.001). No significant difference was observed in the proportion of participants with CD4 counts ≥ 500 cells/μL when HAART-naive participants were compared with HAART-experienced participants (*P* = 0.025). There was no difference in the proportion of participants with TLC \< 1.010^3^/μL in both groups, HAART-naive participants had a significantly higher proportion of participants with TLC 1.0 to 2.0 (*P* = 0.001), while HAART-experienced participants displayed twice the preponderance (*P* \< 0.001).

CD4 count categories stratified by World Health Organization AIDS Clinical Trials Group grades and Centers for Disease Control and Prevention criteria
------------------------------------------------------------------------------------------------------------------------------------------------------

Analysis of the three categories of CD4 counts, WHO/ACTG anemia toxicity and defined TLC grades are as depicted in [Table 4](#t4-idrt-6-2013-025){ref-type="table"}. Based on the analysis of the three categories of CD4 counts and TLC in HAART-naive participants, when TLC was \<1000 μL^−1^, there was a gradual increase in the proportion of patients within the three CD4 categories, from 1.7% in stage 1, 6.8% in stage 2, and to a peak percentage of 91.5% in stage 3 (*P* \< 0.001). With a TLC between 1000 and 2000 μL^−1^, a steady increase was maintained across all the three stages. A similar proportion of patients within the CD4 stages 1 and 3 was observed with a higher proportion of 48.3% in stage 2 when the TLC was \>2000 μL^−1^.

Taking grades of anemia into account, a steady increase in the proportion of participants was observed from stage 1 through stage 3 across all grades.

In patients on HAART, when the TLC was \<1000 μL^−1^, 1000 to 2000 μL^−1^, and \>2000 μL^−1^, patients within category 2 had the highest proportion of participants than category 1 and 3 across all grades. The pattern of incidences of grades 1 and 2 was not consistent, and grades 3 and 4 were absent in HAART-experienced participants.

Discussion
==========

Hematological abnormalities are among the most common complications of HIV, which involves all lineages of blood cells.[@b24-idrt-6-2013-025] Establishing the presence of abnormal hematological manifestations in HAART-naive HIV patients and those on HAART and performing a comparative analysis within the two study groups gives a clear pointer to the overall impact of the treatment regimen in HIV patients. The majority of the study population was \<50 years of age, the most productive segment of the society. These findings are in agreement with previous reports by Akinsete et al[@b25-idrt-6-2013-025] and Erhabor[@b26-idrt-6-2013-025] and as well as other researchers.[@b27-idrt-6-2013-025] The observation of a higher HIV prevalence among young Nigerians is worrisome since the economically viable section of Nigeria's population is most affected by the scourge. Heterosexual transmission as the presumed risk factor in this report is a pointer to the fact that youths are more sexually active and are more prone to high risk behaviors such as maintenance of multiple sex partners that make them vulnerable. Intravenous drug abuse and men that have sex with men (MSM) as risk factors for HIV infection were not observed in our cohort; however, 19 participants (3.8%) in our study within the ages of adolescence and young adulthood were unaware of how they contracted their HIV infection and were not sexually exposed, which could be attributable to prevalent harmful traditional practices such as female genital mutilation, tattooing, group circumcision, and scarification marking performed for adolescent and young adults in our environment.

Results from this study showed that HIV infection may result in deranged hematological indices regardless of age and sex that is ameliorated by use of HAART. The majority of the HIV positive patients were female among both HAART-naive and HAART---experienced participants.

The female preponderance in this study confirms the World Health Organization (WHO) report that HIV/AIDS affects females most severely in sub-Saharan Africa.[@b28-idrt-6-2013-025],[@b29-idrt-6-2013-025] The significant difference in age between HAART-experienced and HAART-naive patients further supports the proposition that HIV/AIDS infection may be acquired at an early age and most probably during the reproductive stage of life. The strict eligibility criteria for HAART initiation, CD4 \< 200 cells/μL or the presence of AIDS- defining illnesses (clinical AIDS) irrespective of CD4,[@b30-idrt-6-2013-025] may also explain why most of the patients on HAART were older than their HAART-naive counterparts in that there could be a time lag between the time a patient tests positive for HIV and the time treatment is initiated, and treatment, once started, is continued throughout the life of the patient.

The incidence of cytopenia in this study was significantly higher in HAART-naive patients than in patients on HAART. Consistent with this report, since the introduction of HAART, several studies have examined the prevalence of anemia, indicating that the prevalence of severe anemia has declined while mild to moderate anemia remains relatively common with use of HAART,[@b4-idrt-6-2013-025],[@b16-idrt-6-2013-025] HIV-1 infection of marrow stromal cells is sufficient to result in anemia and other cytopaenias.[@b7-idrt-6-2013-025]--[@b9-idrt-6-2013-025] A decrease in serum erythropoietin levels,[@b10-idrt-6-2013-025] auto-antibodies to erythropoietin, or marrow suppression by opportunistic infections, tumors, or various medications[@b10-idrt-6-2013-025]--[@b13-idrt-6-2013-025] may also contribute to the anemia commonly observed in HIV-infected persons. HAART may ameliorate many of these effects in an indirect manner simply by decreasing the HIV viral burden.[@b15-idrt-6-2013-025]--[@b17-idrt-6-2013-025] A study[@b18-idrt-6-2013-025] has shown that HAART was associated with an increase in hematopoietic progenitor cell growth. Although the mean platelet count was similar in both HAART-naive and HAART-experienced participants, the relative risk of developing thrombocytopenia in HAART-naive populations was 8 times that of the HAART-experienced. This finding is in sharp contrast to studies conducted previously[@b31-idrt-6-2013-025],[@b32-idrt-6-2013-025] that reported a similar thrombocytopenic incidence in HAART-naive and HAART- experienced patients. Taking into account participants' levels of immunosuppression based on CD4 counts, it was shown that the incidence of grades 1 to 4 anemia among HAART-naive participants with severe, moderate, and mild immunosuppression declined significantly with increased CD4 levels. Although the linear relationship between level of immunity and grades of anemia was lost in HAART-experienced patients, severe grades (3 and 4) were not present in patients on HAART as a result of declines in the prevalence of opportunistis infections and immune-reconstitution, consistent with other reports.[@b15-idrt-6-2013-025],[@b33-idrt-6-2013-025] The laboratory parameter most studied as a potential alternative to CD4 count is TLC. In places where CD4 count testing is not available, the WHO recommends considering treatment for WHO stage 2 disease if TLC is \<1200 μL^−1^. The use of TLC is not recommended in asymptomatic patients.[@b34-idrt-6-2013-025] Evidence frequently cited to support the use of a TLC cutoff of 1200 μL^−1^ (for stage 2 disease) includes a South African cohort study in which TLC \< 1250 μL^−1^ was found to be an equivalent predictor of disease progression compared with CD4 count \< 200 cells/mm^3^.[@b35-idrt-6-2013-025] Our study questions this cutoff because 27.6% of HAART-naive and 12.5% of HAART-experienced participants in this report had CD4 counts \< 200 cells/μL. A previous study in Nigeria reported that a third of patients with CD4 counts \< 200 cells/μL had TLC \> 1200 μL^−1^.[@b36-idrt-6-2013-025] This may imply that an acceptable reproducible cut has been elusive. Further, in an analysis of WHO stage 2 patients in an antiretroviral therapy (ART) program (n = 51 281), CD4 counts and TLC counts were significantly positively correlated.[@b30-idrt-6-2013-025] Using TLC \< 1200 μL^−1^ as a predictor of CD4 count \< 200 cells/μL resulted in 31.5% sensitivity, 96.0% specificity, 95.9% positive predictive value, and 31.6% negative predictive value. Increasing the cutoff value to 1900 μL^−1^ resulted in 67.0% sensitivity, 67.9% specificity, 86.3% positive predictive value, and 40.4% negative predictive value. Taken together, TLC \< 1200 μL^−1^ was a poor predictor of CD4 count \< 200 cells/μL, and over half of patients with CD4 count \< 200 cells/μL would have been inappropriately excluded by TLC-guided treatment with a cutoff of 1200 μL^−1^.[@b37-idrt-6-2013-025] Thus, TLC is of limited usefulness for guiding initiation of ART: some patients with CD4 count \< 200 cells/μL will not be started on ART because their TLC will be \>1200 μL^−1^. Some investigators have suggested that incorporating the hemoglobin level, and perhaps body mass index or platelet count, will improve the accuracy of TLC,[@b36-idrt-6-2013-025],[@b37-idrt-6-2013-025] but it remains to be seen if additional parameters such as these will provide more useful information on a consistent basis.

Conclusion
==========

HAART has the capability of reducing the incidence of anemia, other deranged hematological and immunological parameters associated with disease progression, and death in HIV-infected patients. Total lymphocyte count fails to predict CD4 count \< 200 cells/μL in our cohort; thus, its use in the management and monitoring of HIV-infected patients in our settings is not reliable. In agreement with WHO and other reports, females of reproductive age are at a greater risk of becoming HIV-infected than males, and this could perpetuate documented social complications associated with HIV infection. Continued efforts to educate the vulnerable regarding social lifestyle and possible risk factors associated with HIV cannot be over-emphasized.
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###### 

Demographic and social characteristics of the study population.

  --------------------------------------------------------------------------------------
                           HAART naive\             On HAART\                *P*-value
                           n = 315 (63%)            n = 185 (37%)            
  ------------------------ ------------------------ ------------------------ -----------
  **Age (years)**                                                            

  10--19                   20 (6.3)                 3 (1.6)                  

  20--29                   84 (26.7)                26 (14.1)                

  30--39                   101 (32.1)               57 (30.8)                

  40--49                   63 (20)                  74 (40)                  

  50--59                   21 (6.7)                 16 (8.7)                 

  60--69                   16 (5.1)                 5 (2.7)                  

  70--79                   10 (3.2)                 4 (2.2)                  

  Median ± SD              27.09 ± 16.92 (17--70)   34.43 ± 15.06 (18--67)   0.000

  **Sex**                                                                    

  Male: no (%)             119 (37.8)               67 (36.2)                

   Mean ± SD (min-max)     32.28 ± 17.91 (17--67)   38.77 ± 14.81 (20--67)   

  Female: no (%)           196 (62.2)               118 (63.8)               

   Mean ± SD (min-max)     24.72 ± 14.89 (17--70)   34.08 ± 12.45 (18--66)   

  **Risk factor**                                                            

  Heterosexual             298 (94.6)               180 (97.3)               

  Blood transfusion        3 (0.95)                 0                        

  Iv drug use              0                        0                        

  MSM                      0                        0                        

  Unkown                   14 (4.4)                 5 (2.7)                  

  **Educational status**                                                     

  No formal education      67 (21.3)                33 (17.8)                

  Quaranic education       18 (5.7)                 10 (5.4)                 

  Primary education        54 (17.1)                31 (16.8)                

  Secondary education      119 (37.8)               73 (39.5)                

  Tertiary education       57 (18.1)                38 (20.5)                
  --------------------------------------------------------------------------------------

###### 

Hematological profile, viral load, and cytopenic tendency of the study population.

  Characteristics                            HAART naive               On HAART                  *P*-value
  ------------------------------------------ ------------------------- ------------------------- -----------
  **Participants stratified by HAART use**                                                       
  Sample size (n)                            315                       185                       
  HB (g/dL)                                  9.76 ± 2.82               11.89 ± 1.61              0.000
                                             (95% CI 9.45--10.07)      (95% CI 11.64--1.13)      
  **PCV** \< **30%**                                                                             
  TWBC (×10^3^ μL^−1^)                       5.94 ± 2.91               5.05 ± 1.58               0.000
                                             (95% CI 5.61--6.26)       (95% CI 4.81--5.29)       0.029
  \<2.5                                      19 (6.1)                  3 (1.7)                   
  TLC (×10^3^ μL^−1^)                        1.61 ± 1.02               2.05 ± 1.34               0.000
                                             (95% CI 1.50--1.72)       (95% CI 1.86--2.24)       0.000
  \<1.2                                      94 (32.3)                 11 (10.5)                 
  LC (%)                                     31.85 ± 12.37             46.11 ± 12.70             0.000
                                             (95% CI 30.43--33.28)     (95% CI 44.27--47.90)     0.000
  \<40                                       213 (73.2)                171 (98.3)                
  NC (%)                                     54.98 ± 15.72             38.35 ± 10.49             0.000
                                             (95% CI 53.22--56.73)     (95% CI 36.82--39.87)     0.000
  \<60                                       202 (65.4)                178 (96.7)                
  PLT (×10^3^ μL^−1^)                        297.61 ± 127.19           291.86 ± 95.91            0.000
                                             (95% CI 283.46--311.75)   (95% CI 277.07--306.65)   0.000
  \<150                                      30 (9.6)                  2 (1.2)                   0.000
  CD4 count (cells/μL)                       238.98 ± 216.57           347.73 ± 183.85           0.000
                                             (95% CI 214.93--263.03)   (95% CI 320.77--374.70)   0.000
  \<200                                      168 (53.5)                37 (20.4)                 
  Viral load log10                           5.58 ± 2.23               3.17 ± 1.04               0.000
                                             (95% CI 1.21--2.56)       (95% CI 0.76--1.03)       0.000

**Abbreviations:** TWBC, Total white blood count; LYM%, Lymphocyte percent; Neut%, Neutrophil percent; TLC, Total leukocyte count; PLT, Platelets numbers.

###### 

Study participants stratified by anemia, CD4 count, total leukocyte count, and HAART use.

  Parameter             HAART naive   On HAART     *P*-value
  --------------------- ------------- ------------ -----------
  WHO/ACTG Grade (n)    313           169          
  Grade 1 (9.5--10.5)   68 (21.7)     46 (27.2)    0.176
  Grade 2 (8.0--9.4)    44 (14.1)     15 (8.9)     0.098
  Grade 3 (6.5--7.9)    41 (13.1)     0            0.000
  Grade 4 (\<6.5)       35 (11.2)     0            0.000
  CD4 count (CDC) (n)   \(314\)       \(181\)      
  0--199                168 (53.5)    37 (20.4)    0.000
  200--499              110 (35.0)    110 (60.8)   0.000
  ≥500                  36 (11.5)     34 (18.8)    0.025
  TLC (n)               286           171          
  \<1                   59 (20.6)     26 (15.2)    0.149
  1.0--2.0              140 (48.9)    57 (33.3)    0.001
  \>2.0                 87 (30.4)     88 (51.5)    0.000

###### 

Analysis of the study population stratified by HAART use, TLC, anemia, and CD4 count.

  Variable          CD4 counts   *P*-value               
  ----------------- ------------ ----------- ----------- -------
  **HAART naive**                                        
  TLC                                                    
   \<1.0            54 (91.5)    4 (6.8)     1 (1.7)     0.000
   1.0--2.0         70 (50.0)    58 (41.4)   12 (8.6)    0.000
   \>2.0            24 (27.6)    42 (48.3)   21 (24.1)   0.000
  Anemia                                                 
   9.5--10.5        44 (64.7)    18 (26.5)   6 (8.4)     0.000
   8.0--9.4         26 (59.1)    16 (36.4)   2 (4.5)     0.000
   6.5--7.9         24 (60.0)    13 (32.5)   3 (7.5)     0.000
   \<6.5            27 (77.1)    7 (20.0)    1 (2.9)     0.000
  **On HAART**                                           
  TLC                                                    
   \<1.0            4 (15.4)     19 (70.1)   3 (11.5)    0.000
   1.0--2.0         21 (36.8)    26 (45.6)   10 (17.5)   0.005
   \>2.0            11 (12.5)    50 (56.8)   21 (23.9)   
  Anaemia                                                
   9.5--10.5        5 (10.9)     32 (69.6)   9 (19.6)    0.000
   8.0--9.4         6 (40.0)     8 (53.3)    1 (6.7)     0.020
   6.5--7.9         0            0           0           
   \<6.5            0            0           0           
